CSB 2.009 Note
(3) Paragraph (bm) of s.
161.14 (4), Stats., is created to read:
CSB 2.009 Note
(bm) 2,5-dimethoxy-4-ethylamphetamine, commonly known as DOET;
CSB 2.009 Note
(4) Paragraph (am) of s.
161.14 (7), Stats., is created to read:
CSB 2.009 Note
(am) Aminorex, its salts, optical isomers, and salts of optical isomers;
CSB 2.009 Note
(5) Paragraph (ag) of s.
161.14 (7), Stats., is created to read:
CSB 2.009 Note
(ag) Cathinone;
CSB 2.009 Note
(6) Paragraph (gm) of s.
161.16 (3), Stats., is created to read:
CSB 2.009 Note
(gm) Levo-alphacetylmethadol (LAAM)
CSB 2.009 History
History:
Cr.
Register, August, 1994, No. 464, eff. 9-1-94.
CSB 2.009 Note
CSB 2.23 Additions and amendments to drug schedules. (1) Paragraph (wg) of s.
161.14 (4), Stats., is created to read:
CSB 2.009 Note
(wg) 4-bromo-2,5-dimethoxyphenethylamine;
CSB 2.009 Note
(7) Anabolic steroids. Unless specifically excepted under federal regulations, any compound, material, compound, mixture or preparation containing any quantity of the following anabolic steroids, including any of their esters, isomers, esters of isomers, salts and salts of esters, isomers and esters of isomers, whenever those esters, isomers, esters of isomers, salts and salts [of] esters, isomers and esters of isomers exist within the specific chemical designation:
CSB 2.009 Note
(3) Paragraph (3) (c), of s. 161.18, Stats., is repealed.
CSB 2.009 History
History:
Cr.
Register, November, 1994, No. 467, eff. 12-1-94.
CSB 2.009 Note
CSB 2.24 Addition of butorphanol to schedule IV. (1) Paragraph (c) of s.
961.20 (4), Stats., is created to read:
CSB 2.009 Note
(c) Butorphanol, including any of its isomers and salts of isomers.
CSB 2.009 History
History:
Cr.
Register, November, 1998, No. 515, eff. 12-1-98.
CSB 2.009 Note
CSB 2.25 Addition of remifentanil to schedule II; transfer of dronabinol from schedule II to schedule III; addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil. (1) Section
961.16 (3) (cm), Stats., is amended to read:
CSB 2.009 Note
(cm) Carfentanil;
CSB 2.009 Note
(xm) Remifentanil;
CSB 2.009 Note
(3) Section 961.16 (10) (a), Stats., is repealed.
CSB 2.009 Note
(4) Section
961.18 (4m), Stats., is created to read:
CSB 2.009 Note
(4m) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6aR-trans)-6a, 7, 8, 10a-tetrahydro-6, 6. 9-trimethyl-3-pentyl-6H-dibenzo(b, d)pyran-1-ol, and (-)-delta-9-(trans)-tetrahydrocannabinol.)
CSB 2.009 Note
(o) Zaleplon.
CSB 2.009 Note
(p) Zolpidem.
CSB 2.009 Note
(at) Fenproporex.
CSB 2.009 Note
(bu) Modafinil.
CSB 2.009 Note
(f) Sibutramine.
CSB 2.009 History
History:
Cr.
Register, July, 2000, No. 535, eff. 8-1-00.
CSB 2.009 Note
CSB 2.26 Addition of dihydroetorphine to schedule II. (1) Section
961.16 (2) (a) 4r., Stats., is created to read:
CSB 2.009 Note
4r. Dihydroetorphine.
CSB 2.009 History
History:
CR 01-071: Cr.
Register November 2001 No. 551, eff. 12-1-01.
CSB 2.009 Note
CSB 2.28 Addition of dichloralphenazone to schedule IV. (1) Section
961.20 (2) (cs), Stats., is created to read:
CSB 2.009 History
History:
CR 02-025: Cr.
Register October 2002 No. 562, eff. 11-1-02.
CSB 2.009 Note
CSB 2.29 Transfer of buprenorphine from schedule V to schedule III. (1) Section
961.18 (5m), Stats., is created to read:
CSB 2.009 NoteSection 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
CSB 2.009 Note
(a) Buprenorphine
CSB 2.009 History
History:
CR 03-056: cr.
Register January 2004 No. 577, eff. 2-1-04.
CSB 2.009 Note
CSB 2.30 Addition of gamma-hydroxybutyric acid to schedule III. (1) Section
961.18 (3) (o), Stats., is created to read:
CSB 2.009 NoteSection 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act:
CSB 2.009 Note
1. Gamma-hydroxybutyric acid.
CSB 2.009 History
History:
CR 03-057: cr.
Register January 2004 No. 577, eff. 2-1-04.
CSB 2.009 Note
CSB 2.31 Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I. (1) Section
961.14 (4) (wh), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as “2C-T-7";
CSB 2.009 History
History:
CR 06-058: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.32 Addition of N- benzylpiperazine (BZP) to schedule I. (1) Section
961.14 (7) (q), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (7) (q) N- benzylpiperazine, commonly known as “BZP."
CSB 2.009 History
History:
CR 06-058: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I. (1) Section
961.14 (4) (wi), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT";
CSB 2.009 History
History:
CR 06-059: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). (1) Section
961.14 (4) (wj), Stats., is created to read:
CSB 2.009 NoteSection 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT";
CSB 2.009 History
History:
CR 06-059: cr.
Register April 2007 No. 616, eff. 5-1-07.
CSB 2.009 Note
CSB 2.35 Addition of lisdexamfetamine to schedule II. (1) Section
961.16 (5) (e), Stats., is created to read:
CSB 2.009 NoteSection 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM."
CSB 2.009 History
History:
CR 10-112: cr.
Register April 2011 No. 664, eff. 5-1-11.
CSB 2.009 Note
CSB 2.36 Addition of tramadol to schedule IV. Section
961.20 (4) (e), Stats., is created to read:
CSB 2.009 NoteSection 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers. CSB 2.009 History
History:
cr. Affirmative action order under s.
968.11 (4), Stats.,
Register August 2014 No. 704, eff. 9-1-14;
CR 15-008: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
CSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2014 No. 706, eff. 11-1-14;
CR 15-007: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
CSB 2.38 Addition of suvorexant to schedule IV. Section
961.20 (2) (mr), Stats., is created to read:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2014 No. 706, eff. 11-1-14;
CR 15-009: cr.
Register October 2015 No. 718, eff. 11-1-15.
CSB 2.009 Note
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene,
naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2015 No. 711B, eff. 4-1-15;
CR 15-068: cr.
Register August 2016 No. 728, eff. 9-1-16.
CSB 2.009 Note
CSB 2.40 Exclusion of [123
I]ioflupane. Section
961.16 (2) (b), Stats., is amended to read:
CSB 2.009 Note
(b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2015 No. 718A3, eff. 10-19-15; correction made under s.
35.17, Stats.,
Register October 2015 No. 718;
CR 16-060: cr.
Register May 2017 No. 737, eff. 6-1-17.
CSB 2.009 Note
CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections
961.14 (2) (eu) and
(ey) are created to read:
CSB 2.009 Note
961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
CSB 2.009 Note
(ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2016 No. 728, eff. 7-18-16;
CR 16-081: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.42 Scheduling of furanyl fentanyl. Section
961.14 (2) (ne) is created to read:
CSB 2.009 Note
961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
CSB 2.009 History
History:
EmR1626: emerg. cr., eff. 9-1-16;
CR 16-059: cr.
Register May 2017 No. 737, eff. 6-1-17.
CSB 2.009 Note
CSB 2.43 Addition of brivaracetam to schedule V. Section
961.22 (6), Stats., is created to read:
CSB 2.009 Note
961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register September 2016 No. 729, eff. 9-26-16;
CR 17-009: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.009 Note
CSB 2.44 Addition of thiafentanil to schedule II. Section
961.16 (3) (zx), Stats., is created to read:
CSB 2.009 Note
961.16 (3) (zx) Thiafentanil.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2016 No. 730, eff. 10-3-16;
CR 17-007: cr.
Register July 2017 No. 739, eff. 8-1-17.
